Matthew D. Breyer

机构：Johnson & Johnson (United States), Eli Lilly (United States) · ORCID：0000-0003-1880-371X

发表论文 316 篇 · 总被引 19903 次 · h-index 77

代表论文

• Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies (2022 · Cell Metabolism · 被引 254)
• Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine (2024 · Kidney International · 被引 36)
• Cyclooxygenase-2 contributes to diabetic nephropathy through glomerular EP4 receptor (2022 · Prostaglandins & Other Lipid Mediators · 被引 15)
• Mitochondrial and NAD+ metabolism predict recovery from acute kidney injury in a diverse mouse population (2023 · JCI Insight · 被引 10)
• Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I2 Receptor (2023 · Journal of the American Society of Nephrology · 被引 7)
• Tackling AKI (2023 · Journal of the American Society of Nephrology · 被引 3)